Cargando…
Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models
BACKGROUND: HER2 is an oncogene, expression of which leads to poor prognosis in 30% of breast cancer patients. Although trastuzumab is apparently an effective therapy against HER2-positive tumors, its systemic toxicity and resistance in the majority of patients restricts its applicability. In this s...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412708/ https://www.ncbi.nlm.nih.gov/pubmed/22824293 http://dx.doi.org/10.1186/1741-7015-10-80 |